• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

KIF18B Polyklonaler Antikörper

KIF18B Polyklonal Antikörper für IP, Indirect ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

IP, Indirect ELISA

Konjugation

Unkonjugiert

Kat-Nr. : 33139-1-PBS

Synonyme

Kinesin-like protein KIF18B

Filter:
  • Immunoprecipitation (IP) experiment of Jurkat cells using KIF18B Polyclonal antibody (33139-1-AP)

    IP experiment of Jurkat using 33139-1-AP (same clone as 33139-1-PBS)

    IP result of anti-KIF18B (IP:33139-1-AP, 4ug; Detection:33139-1-AP 1:400) with Jurkat cells lysate 1360 ug. This data was developed using the same antibody clone with 33139-1-PBS in a different storage buffer formulation.

Geprüfte Anwendungen

Produktinformation

33139-1-PBS bindet in IP, Indirect ELISA KIF18B und zeigt Reaktivität mit human

Getestete Reaktivität human
Wirt / Isotyp Kaninchen / IgG
Klonalität Polyklonal
Typ Antikörper
Immunogen KIF18B fusion protein Ag36663
Vollständiger Name kinesin family member 18B
Berechnetes Molekulargewicht852 aa, 93 kDa/833 aa, 91 kDa
Beobachtetes Molekulargewicht100 kDa
GenBank-ZugangsnummerBC136590
Gene symbol KIF18B
Gene ID (NCBI) 146909
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Antigen-Affinitätsreinigung
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

KIF18B is a key member of the kinesin-8 family, involved in regulating various physiological processes such as microtubule length, spindle assembly, and chromosome alignment. This article briefly introduces the structure and physiological functions of KIF18B, examines its role in malignant tumors, and the associated carcinogenic signaling pathways such as PI3K/AKT, Wnt/β-catenin, and mTOR pathways. Research indicates that the upregulation of KIF18B enhances tumor malignancy and resistance to radiotherapy and chemotherapy. KIF18B could become a new target for anticancer drugs, offering significant potential for the treatment of malignant tumors and reducing chemotherapy resistance (PMID: 39259333).